Related references
Note: Only part of the references are listed.AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset
David Goertsen et al.
NATURE NEUROSCIENCE (2022)
AAV capsid design: A Goldilocks challenge
S. Zolotukhin et al.
TRENDS IN MOLECULAR MEDICINE (2022)
Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy
Rachael A. Potter et al.
HUMAN GENE THERAPY (2021)
Current Clinical Applications of In Vivo Gene Therapy with AAVs
Jerry R. Mendell et al.
MOLECULAR THERAPY (2021)
The clinical landscape for AAV gene therapies
Dmitry A. Kuzmin et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Structurally Mapping Antigenic Epitopes of Adeno-associated Virus 9: Development of Antibody Escape Variants
Shanan N. Emmanuel et al.
JOURNAL OF VIROLOGY (2021)
Gene therapy community grapples with toxicity issues, as pipeline matures
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2021)
The membrane associated accessory protein is an adeno-associated viral egress factor
Zachary C. Elmore et al.
NATURE COMMUNICATIONS (2021)
Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species
Mohammadsharif Tabebordbar et al.
CELL (2021)
Receptor Switching in Newly Evolved Adeno-associated Viruses
L. Patrick Havlik et al.
JOURNAL OF VIROLOGY (2021)
Engineering adeno-associated virus vectors for gene therapy
Chengwen Li et al.
NATURE REVIEWS GENETICS (2020)
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Dan Wang et al.
CELL (2020)
Immunity to Cas9 as an Obstacle to Persistent Genome Editing
Veronica Gough et al.
MOLECULAR THERAPY (2020)
Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy
James M. Wilson et al.
HUMAN GENE THERAPY (2020)
Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy A Nonrandomized Controlled Trial
Jerry R. Mendell et al.
JAMA NEUROLOGY (2020)
Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach
L. Patrick Havlik et al.
JOURNAL OF VIROLOGY (2020)
Adeno-Associated Virus-Induced Dorsal Root Ganglion Pathology
Juliette Hordeaux et al.
HUMAN GENE THERAPY (2020)
Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme
Zachary C. Elmore et al.
JCI INSIGHT (2020)
Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants
Jonas Weinmann et al.
NATURE COMMUNICATIONS (2020)
Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy
Christopher E. Nelson et al.
NATURE MEDICINE (2019)
Adeno-associated virus vector as a platform for gene therapy delivery
Dan Wang et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells
Yi-Li Min et al.
SCIENCE ADVANCES (2019)
Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy
Angela L. McCall et al.
CURRENT GENE THERAPY (2019)
Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids
Qin Huang et al.
PLOS ONE (2019)
Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN
Christian Hinderer et al.
HUMAN GENE THERAPY (2018)
Mapping the Structural Determinants Required for AAVrh. 10 Transport across the Blood-Brain Barrier
Blake H. Albright et al.
MOLECULAR THERAPY (2018)
The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice
Juliette Hordeaux et al.
MOLECULAR THERAPY (2018)
AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice
Chady H. Hakim et al.
JCI INSIGHT (2018)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion
Longping Victor Tse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
Caroline Le Guiner et al.
NATURE COMMUNICATIONS (2017)
In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Mohammadsharif Tabebordbar et al.
SCIENCE (2016)
In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy
Sourav R. Choudhury et al.
MOLECULAR THERAPY (2016)
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Benjamin E. Deverman et al.
NATURE BIOTECHNOLOGY (2016)
Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing
Kei Adachi et al.
NATURE COMMUNICATIONS (2014)
Engraftment of a Galactose Receptor Footprint onto Adeno-associated Viral Capsids Improves Transduction Efficiency
Shen Shen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Structural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9
Michael A. DiMattia et al.
JOURNAL OF VIROLOGY (2012)
Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle
Aravind Asokan et al.
NATURE BIOTECHNOLOGY (2010)
A robust and high-throughput Cre reporting and characterization system for the whole mouse brain
Linda Madisen et al.
NATURE NEUROSCIENCE (2010)
Distinct Regulatory Cascades Govern Extraocular and Pharyngeal Arch Muscle Progenitor Cell Fates
Ramkumar Sambasivan et al.
DEVELOPMENTAL CELL (2009)
Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle
AR Brooks et al.
JOURNAL OF GENE MEDICINE (2004)
Share Paper
